Text Size

Reoperation Rates and Disease Costs for Primary Open-Angle Glaucoma Patients in the United States Treated with Incisional Glaucoma Surgery

Randy Craven E., Singh I.P., Yu T.M., Rhoten S., Sadruddin O.R., Sheybani A.


  • 2021
  • Ophthalmology Glaucoma
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Post-Approval studies/RWE

  • Affiliations

    Wilmer Eye Institute, John Hopkins University, Bethesda, MD, United States; The Eye Centers of Racine & Kenosha, Ltd, Racine, WI, United States; Life Sciences, Guidehouse, Inc, San Francisco, CA, United States; Global Medical Affairs, Santen USA, Emeryville, CA, United States; Ophthalmology & Visual Sciences, Washington University School of Medicine, St. Louis, MO, United States

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.


Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.


Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022